T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.
T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.
复制标题
DOI：
10.1155/2017/6894374
复制
发表时间：
2017
影响因子：
4.6
通讯作者：
Balog A
中科院分区：
文献类型：
--
作者：
Dulic S;Vásárhelyi Z;Sava F;Berta L;Szalay B;Toldi G;Kovács L;Balog A
关于生物疗法对类风湿性关节炎T细胞表型的影响的数据有限。在这里，我们使用流式细胞术前瞻性地测量了15个循环T细胞亚型的百分比。我们获得了30例抗肿瘤坏死因子应答者、19例继发性抗肿瘤坏死因子无应答者和43例IL-6R拮抗剂应答者在生物治疗前、8周和至少6个月的横向和纵向数据。未经治疗的类风湿性关节炎患者和健康对照组也包括在内。主要研究结果如下：(1)长期治疗的RA患者外周血中调节性T细胞(Tregs)比例降低，但在抗肿瘤坏死因子应答组和无应答组中，单纯CD4+和CD8+细胞比例低于未治疗组和正常对照组，而促炎细胞Th1、Th2、Th17细胞和人类白细胞抗原DR+活化细胞比例高于未治疗组和健康对照组，IL-6R应答组Th1比例降低，Th2和Th17比例升高；(4)CD4CD69比值 <； 为2.43，提示抗肿瘤坏死因子治疗的良好疗效尚待证实。这项研究提供了关于这些生物疗法对类风湿关节炎患者T细胞生态趋向性的长期影响的全面信息。我们研究的ClinicalTrials.gov注册编号是NCT03266822。
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF nonresponders, and 43 IL-6R antagonist responders, before, 8 weeks and at least 6 months after biological therapy. Untreated RA patients and healthy controls were also included. The important findings are the following: (1) the proportion of regulatory T-cells (Tregs) which are decreased in untreated RA patients becomes normal in all long-term-treated groups; (2) in anti-TNF responders as well as in nonresponders, the frequencies of naïve CD4+ and CD8+ cells are lower, whereas those of proinflammatory Th1, Th2, and Th17 cells and HLA-DR+-activated cells are higher than those in untreated RA or healthy controls; (3) in IL-6R responders, Th1 proportion is decreased, while that of Th2 and Th17 is increased as compared to that in anti-TNF-treated patients and controls; (4) pending confirmation, a CD4CD69 ratio < 2.43 at baseline, could be useful to predict a good therapeutic response to anti-TNF therapy. This study provides comprehensive information regarding the long-term impacts of those biological therapies on the ecotaxis of T-cells in RA. The ClinicalTrials.gov registration number of our study is NCT03266822.
登录
查看更多内容
影响因子：
4.9
作者：
Shiozawa K;Yamane T;Murata M;Yoshihara R;Tsumiyama K;Imura S;Shiozawa S
通讯作者：
Shiozawa S
影响因子：
9.1
作者：
Chen Lina;Wang Conghua;Zhu Ping
通讯作者：
Zhu Ping
影响因子：
--
作者：
Samson, Maxime;Audia, Sylvain;Bonnotte, Bernard
通讯作者：
Bonnotte, Bernard
影响因子：
4.9
作者：
Carrier N;Marotta A;de Brum-Fernandes AJ;Liang P;Masetto A;Ménard HA;Maksymowych WP;Boire G
通讯作者：
Boire G
影响因子：
5.5
作者：
Aeberli, D;Seitz, M;Villiger, PM
通讯作者：
Villiger, PM